Outcomes related to respiratory syncytial virus with an abbreviated palivizumab regimen in children with congenital heart disease: a descriptive analysis.
Journal
CMAJ open
ISSN: 2291-0026
Titre abrégé: CMAJ Open
Pays: Canada
ID NLM: 101620603
Informations de publication
Date de publication:
Historique:
entrez:
21
2
2019
pubmed:
21
2
2019
medline:
21
2
2019
Statut:
epublish
Résumé
It has been hypothesized that 4 doses of palivizumab, a neutralizing monoclonal antibody against respiratory syncytial virus (RSV), administered during a fixed-date RSV season may reduce hospital admissions comparably to the standard 5-dose schedule. We report outcomes in children with congenital heart disease approved to receive this 4-dose palivizumab schedule in British Columbia. We performed a population-based descriptive cohort analysis of all 406 approved palivizumab courses over 4 seasons (2012/13 to 2015/16) in 325 children with hemodynamically significant congenital heart disease enrolled in the British Columbia RSV Immunoprophylaxis Program. The primary outcome was in-season hospital admission for potential RSV-related lower respiratory tract infection (LRTI). Secondary outcomes include timing of admission in relation to dosing. Analysis was by intention-to-treat. Of the 406 approved palivizumab courses, 391 were administered. In 33 cases (8.4%), an additional dose was given immediately after cardiac bypass surgery. There were 17 RSV-confirmed hospital admissions (median age of children 5.9 mo [interquartile range 4-10 mo]) and 8 admissions in which the child was not tested for RSV, for a maximum of 25 potential RSV-related admissions (6.2 per 100 approvals [95% confidence interval 4.0-9.0]). Twenty-four (96%) of the 25 admissions occurred within the 4-dose palivizumab dosing period, and the remaining admission occurred 52 days after the fourth dose. Sixty-four (72%) of 89 admissions were RSV-negative; the baseline clinical characteristics of these children were not different from those of children with RSV-confirmed admissions. In infants with hemodynamically significant congenital heart disease, a 4-dose fixed-date palivizumab schedule over a 6-month season provided seasonal protection comparable to that in a clinical trial involving a standard 5-dose schedule. Because RSV was responsible for only 19% of admissions for LRTI in our cohort, it is critical to continue to emphasize other preventive measures, including family education toward proper hand hygiene, breast-feeding and limiting infectious exposures in children at high risk.
Sections du résumé
BACKGROUND
BACKGROUND
It has been hypothesized that 4 doses of palivizumab, a neutralizing monoclonal antibody against respiratory syncytial virus (RSV), administered during a fixed-date RSV season may reduce hospital admissions comparably to the standard 5-dose schedule. We report outcomes in children with congenital heart disease approved to receive this 4-dose palivizumab schedule in British Columbia.
METHODS
METHODS
We performed a population-based descriptive cohort analysis of all 406 approved palivizumab courses over 4 seasons (2012/13 to 2015/16) in 325 children with hemodynamically significant congenital heart disease enrolled in the British Columbia RSV Immunoprophylaxis Program. The primary outcome was in-season hospital admission for potential RSV-related lower respiratory tract infection (LRTI). Secondary outcomes include timing of admission in relation to dosing. Analysis was by intention-to-treat.
RESULTS
RESULTS
Of the 406 approved palivizumab courses, 391 were administered. In 33 cases (8.4%), an additional dose was given immediately after cardiac bypass surgery. There were 17 RSV-confirmed hospital admissions (median age of children 5.9 mo [interquartile range 4-10 mo]) and 8 admissions in which the child was not tested for RSV, for a maximum of 25 potential RSV-related admissions (6.2 per 100 approvals [95% confidence interval 4.0-9.0]). Twenty-four (96%) of the 25 admissions occurred within the 4-dose palivizumab dosing period, and the remaining admission occurred 52 days after the fourth dose. Sixty-four (72%) of 89 admissions were RSV-negative; the baseline clinical characteristics of these children were not different from those of children with RSV-confirmed admissions.
INTERPRETATION
CONCLUSIONS
In infants with hemodynamically significant congenital heart disease, a 4-dose fixed-date palivizumab schedule over a 6-month season provided seasonal protection comparable to that in a clinical trial involving a standard 5-dose schedule. Because RSV was responsible for only 19% of admissions for LRTI in our cohort, it is critical to continue to emphasize other preventive measures, including family education toward proper hand hygiene, breast-feeding and limiting infectious exposures in children at high risk.
Identifiants
pubmed: 30782771
pii: 7/1/E88
doi: 10.9778/cmajo.20180167
pmc: PMC6380901
doi:
Types de publication
Journal Article
Langues
eng
Pagination
E88-E93Informations de copyright
Copyright 2019, Joule Inc. or its licensors.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Clin Infect Dis. 2015 Aug 15;61(4):515-6
pubmed: 25904371
Pediatrics. 1996 Jan;97(1):152-3
pubmed: 8545218
Can J Cardiol. 2017 Feb;33(2):199-208
pubmed: 28043739
Pediatr Infect Dis J. 1998 Feb;17(2):110-5
pubmed: 9493805
JAMA Pediatr. 2015 Apr;169(4):341-8
pubmed: 25706618
PLoS One. 2017 Apr 24;12(4):e0176152
pubmed: 28437470
J Pediatr. 2003 Oct;143(4):532-40
pubmed: 14571236
JAMA Pediatr. 2016 Feb;170(2):174-6
pubmed: 26720836
Pediatrics. 2014 Aug;134(2):415-20
pubmed: 25070315
Clin Infect Dis. 2015 Aug 15;61(4):506-14
pubmed: 25904370
J Infect Dis. 2018 Apr 11;217(9):1356-1364
pubmed: 29390105
Eur J Pediatr. 2018 Sep;177(9):1407-1408
pubmed: 29740691
Ther Drug Monit. 2002 Jun;24(3):444-5
pubmed: 12021640
Lancet. 2017 Sep 2;390(10098):946-958
pubmed: 28689664
J Immunol. 2014 Feb 1;192(3):948-57
pubmed: 24391215
Paediatr Child Health. 2015 Aug-Sep;20(6):321-33
pubmed: 26435673
Pediatrics. 1998 Sep;102(3 Pt 1):531-7
pubmed: 9738173
Pediatr Infect Dis J. 2017 May;36(5):445-450
pubmed: 28403044